The national law firm of Parker Waichman LLP has filed a lawsuit in the Superior Court of New Jersey, Atlantic County Law Division against Merck Sharp & Dohme Corp., and Merck & Co., Inc. on behalf of woman in Mississippi alleging that the drug Fosamax caused her to suffer a left femur fracture.
The lawsuit says that the plaintiff used Fosamax as prescribed starting in December 2005. In 2010, the woman suffered a left subtrochanteric femur fracture, which has caused her severe mental and physical pain, as well as emotional distress, permanent injury, and economic loss due to medical expenses and living related expenses due to a new lifestyle.
According to the lawsuit, the injuries suffered by the plaintiff were caused as a result of using Fosamax for several years. The lawsuit alleges that the defendants knew that Fosamax could cause multiple stress fractures and failed to adequately warn consumers and their physicians. The plaintiff alleges that she would have not used Fosamax if she had been fully informed about the risks.
The FDA approved Fosamax, a bisphosphonate, to prevent bone loss due to osteoporosis. In October of 2010, the agency updated the warning label of bisphosphonates to include a warning about the increased risk of atypical femur fractures. The drug has also been linked to esophageal cancer and osteonecrosis of the jaw.
The FDA recently found “little benefit of continued bisphosphonate treatment beyond 5 years,” Parker Waichman reports.